



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

M GNN-5315DV1

09/627,896 07/27/00  
09/627896

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
025291	HM22/1002	GAMBEL, P.	
AMERICAN HOME PRODUCTS CORPORATION		EXAMINER	
FIVE GIRALDA FARMS			
PATENT LAW			
MADISON NJ 07940			

1644 ART UNIT PAPER NUMBER

1644 8

DATE MAILED:

10/2/01

This is a communication from the examiner in charge of your application.  
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

Responsive to communication(s) filed on 7/17/01

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 1 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

Claim(s) 1-5 is/are pending in the application.

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

Claim(s) \_\_\_\_\_ is/are allowed.

Claim(s) \_\_\_\_\_ is/are rejected.

Claim(s) \_\_\_\_\_ is/are objected to.

Claim(s) 1-5 are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

The proposed drawing correction, filed on \_\_\_\_\_ is  approved  disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All  Some\*  None of the CERTIFIED copies of the priority documents have been received.

received in Application No. (Series Code/Serial Number) \_\_\_\_\_

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of Reference Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

SEE OFFICE ACTION ON THE FOLLOWING PAGES--

BEST AVAILABLE COPY

Serial No. 09/627896  
Art Unit 1644

#### **DETAILED ACTION**

1. Applicant's communication, filed 7/27/00, has placed this application in compliance with the Sequence Rules.
2. Prior to setting forth the restriction requirement, it is pointed out that the claims are drawn to patentably distinct methods. The methods target different diseases which are distinct because the pathological conditions differ in etiologies and therapeutic endpoints which require non-coextensive searches to such an extent that they are considered separately patentable. See 5, paragraph 2 of the instant specification. Therefore, the restriction will be set forth for each of the various groups, irrespective of the format of the claims, because these are not proper species.
3. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
  - I. Claims 1, drawn to methods of inhibiting the interaction of B7-2-expressing cells as it reads on autoimmune diseases with B7-2-specific antibodies, classified in Class 424, subclass 130.1.
  - II. Claims 1, drawn to methods of inhibiting the interaction of B7-2-expressing cells as it reads on inflammatory disorders with B7-2-specific antibodies, classified in Class 424, subclass 130.1.
  - III. Claims 1, drawn to methods of inhibiting the interaction of B7-2-expressing cells as it reads on infectious diseases with B7-2-specific antibodies, classified in Class 424, subclass 130.1.
  - IV. Claims 1-4, drawn to methods of inhibiting the interaction of B7-2-expressing cells as it reads on transplanted tissue with B7-2-specific antibodies, classified in Class 424, subclass 130.1.
  - V. Claim 5, drawn to methods of inhibiting immune responses to transplanted tissue with B7-1-specific and B7-2-specific antibodies, classified in Class 424, subclass 130.1.
4. Inventions I, II, III, IV and V are different methods which require different ingredients, process steps and endpoints. Therefore, they are patentably distinct.
5. Because these inventions are distinct for the reasons given above and the search required for any group from Groups I-V is not required for any other group from Groups I-V and Groups I-V have acquired a separate status in the art because the searches are not co-extensive and encompass divergent subject matter, restriction for examination purposes as indicated is proper.
6. This application contains claims directed to the following patentably distinct species of the claimed Group I : wherein the autoimmune disease is:
  - A) SLE,
  - B) diabetes,
  - C) arthritis, or
  - D) multiple sclerosis.

These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

7. This application contains claims directed to the following patentably distinct species of the claimed Group I : wherein the inflammatory disorders is:

- A) insulitis,
- B) IBD, or
- C) inflammatory dermatitis.

These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

8. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

9. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gabel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Phillip Gabel

Phillip Gabel, PhD.  
Primary Examiner  
Technology Center 1600  
September 28, 2001